百令膠囊聯(lián)合利拉魯肽治療早期糖尿病腎病的療效分析

葛洪燕

[摘要] 目的 分析早期糖尿病腎病患者應(yīng)用百令膠囊與利拉魯肽聯(lián)合治療的臨床價值以及對其產(chǎn)生的影響。方法 選取筆者所在醫(yī)院2018年6月—2019年4月收治的98例早期糖尿病腎病患者，根據(jù)抽簽法將其平均分成兩組（試驗組與參照組），一組納入49例。參照組運(yùn)用利拉魯肽單一治療，試驗組運(yùn)用百令膠囊與利拉魯肽聯(lián)合治療。對其治療前后三酰甘油、血尿素氮、總膽固醇、糖化血紅蛋白、空腹血糖以及臨床不良反應(yīng)發(fā)生率進(jìn)行統(tǒng)計分析。 結(jié)果 治療前兩組對比均差異無統(tǒng)計學(xué)意義（P>0.05），治療后試驗組三酰甘油、血尿素氮、總膽固醇等指標(biāo)均低于參照組同等指標(biāo)，差異有統(tǒng)計學(xué)意義（P<0.05）;治療前兩組患者空腹血糖與糖化血紅蛋白對比差異無統(tǒng)計學(xué)意義（P>0.05），治療后試驗組空腹血糖與糖化血紅蛋白均低于參照組同等指標(biāo)，差異有統(tǒng)計學(xué)意義（P<0.05）;試驗組不良反應(yīng)總發(fā)生率4.08%（2/49）低于參照組不良反應(yīng)總發(fā)生率18.37%（9/49），差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 治療早期糖尿病腎病選取百令膠囊與利拉魯肽聯(lián)合治療，可全面改善患者臨床各項指標(biāo)水平，臨床不良反應(yīng)發(fā)生率較低，用藥安全系數(shù)較高。

[關(guān)鍵詞] 糖尿病;腎病;治療效果;百令膠囊;聯(lián)合治療;利拉魯肽

[中圖分類號] R587.2? ? ? ? ? [文獻(xiàn)標(biāo)識碼] A? ? ? ? ? [文章編號] 1672-4062（2020）09（b）-0156-03

Efficacy Analysis of Bailing Capsule Combined with Liraglutide in the Treatment of Early Diabetic Nephropathy

GE Hong-yan

Department of Endocrinology， Luzhong Hospital of Peking University， Zibo， Shandong Province， 255400 China

[Abstract] Objective To analyze the clinical value and influence of Bailing capsule combined with liraglutide in patients with early diabetic nephropathy. Methods A total of 98 patients with early diabetic nephropathy admitted to the author's hospital from June 2018 to April 2019 were selected and divided into 2 groups （test group and reference group） according to the lottery method， and one group included 49 cases. The reference group was treated with liraglutide alone， and the experimental group was treated with Bailing capsules and liraglutide in combination. The incidence of triacylglycerol， blood urea nitrogen， total cholesterol， glycosylated hemoglobin， fasting blood glucose and clinical adverse reactions before and after treatment were statistically analyzed. Results There was no statistically significant difference between the two groups before treatment（P>0.05）. After treatment， the indicators of triacylglycerol， blood urea nitrogen， and total cholesterol in the test group were lower than the same indicators in the reference group， the difference was statistically significant（P<0.05）; Before treatment， there was no statistically significant difference in fasting blood glucose and glycosylated hemoglobin between the two groups of patients（P>0.05）. After treatment， the fasting blood glucose and glycosylated hemoglobin of the test group were lower than the same indicators in the reference group， the difference was statistical significance（P<0.05）; the test group with the total incidence rate of 4.08%（2/49） cases was lower than the total incidence rate of 18.37% （9/49） cases in the reference group， the difference was statistically significant（P<0.05）. Conclusion The combination therapy of Bailing capsule and liraglutide for the treatment of early diabetic nephropathy can comprehensively improve the level of various clinical indicators in patients， with a lower incidence of clinical adverse reactions and a higher drug safety factor.